By Marguerite Ward 1. Gilead’s numbers are looking good: The California-based biopharmaceutical company continues to see success with its HIV drugs (Stribild, Viread ect.) and Hepatitis C drugs (Sovaldi and Harvoni). Gilead’s stock is up 6.24 percent year-to-date at $100.14, swiftly outpacing the NASDAQ composite index’s 1 percent decline over the same period. Its earnings per … Continue reading
Investors are bracing for what could be a bumpy ride after the People’s Bank of China devalued the yuan by nearly 2 percent overnight. The VIX index, which measures market volatility, peaked at more than 14 percent Tuesday afternoon. Meanwhile, the Dow plunged over 200 points, the S&P 500 slipped by about 1 percent and … Continue reading
The stock market closed higher on Friday, riding the good news of this month’s jobs report. The U.S. economy added 223,000 non-farm jobs in April, according to Friday’s report from the Bureau of Labor Statistics. The number exceeded expectation and signals brighter days ahead for an economy some feared was stalling. The promising numbers come after … Continue reading
